Billiontoone (NASDAQ:BLLN) Price Target Cut to $100.00 by Analysts at Guggenheim

Key Points

• Guggenheim cut its price target on Billiontoone from $120 to $100 but maintained a "buy" rating, implying roughly a 40.5% upside from the current share price.
• Billiontoone beat quarterly estimates with $0.11 EPS versus $0.04 expected and revenue of $96.05M (up 113% year-over-year) compared with $85.85M forecast.
• Analysts collectively rate the stock a Moderate Buy (six Buy, three Hold, one Sell) with an average target of $126.71, and institutions—most notably Baillie Gifford—initiated sizable positions (~$103.8M).

Billiontoone (NASDAQ:BLLN - Get Free Report) had its price objective dropped by investment analysts at Guggenheim from $120.00 to $100.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. Guggenheim's price target indicates a potential upside of 40.52% from the company's current price.

Several other analysts have also commented on BLLN. JPMorgan Chase & Co. cut their target price on shares of Billiontoone from $150.00 to $145.00 and set an "overweight" rating for the company in a research note on Wednesday, December 10th. Wells Fargo & Company reduced their price objective on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating for the company in a research note on Thursday, March 5th. Jefferies Financial Group began coverage on Billiontoone in a report on Monday, December 1st. They set a "hold" rating and a $117.00 target price for the company. BTIG Research cut their price objective on Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a report on Thursday, March 5th. Finally, Stifel Nicolaus assumed coverage on shares of Billiontoone in a report on Monday, December 1st. They issued a "buy" rating and a $145.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $126.71.

Billiontoone Price Performance

Shares of NASDAQ BLLN traded up $1.62 during mid-day trading on Monday, hitting $71.17. The company had a trading volume of 83,517 shares, compared to its average volume of 268,642. Billiontoone has a 12 month low of $61.96 and a 12 month high of $138.70. The firm has a market cap of $3.27 billion and a PE ratio of 338.89. The company has a current ratio of 11.69, a quick ratio of 11.32 and a debt-to-equity ratio of 0.12. The firm's 50 day simple moving average is $80.10.

Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings data on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million for the quarter, compared to analyst estimates of $85.85 million. The company's revenue was up 113.0% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BLLN. Green Alpha Advisors LLC bought a new position in shares of Billiontoone during the 4th quarter valued at $436,000. FNY Investment Advisers LLC bought a new stake in shares of Billiontoone during the 4th quarter worth about $497,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Billiontoone during the 4th quarter valued at about $13,373,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone in the 4th quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Billiontoone during the fourth quarter worth approximately $1,348,000.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.